TL-895

TL-895 is a potent, orally available, highly selective irreversible small molecule inhibitor of Bruton's tyrosine kinase (BTK) and bone marrow tyrosine kinase X-linked (BMX). It acts by covalently binding to BTK, thereby preventing its activity and disrupting signaling pathways involved in the growth and survival of malignant B cells. TL-895 is being developed primarily for hematologic malignancies and related disorders such as myelofibrosis, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), indolent systemic mastocytosis, acute myeloid leukemia (AML), and other B-cell malignancies. The drug is administered orally in tablet or capsule form. It has demonstrated preclinical efficacy in models of B-cell lymphoma and is currently under investigation in multiple clinical trials for these indications[1][2][3][4][5][6].

Other names

M7583M-7583M 7583TL 895TL895TL-895